2-[18F]fluoro-2-deoxyglucose and glucose uptake in malignant gliomas before and after radiotherapy: Correlation with outcome

Clinical Cancer Research

Volumn 8, Issue 4, 2002, Pages 971-979

  Spence, Alexander M ^a   Muzi, Mark ^a   Graham, Michael M ^a   O'Sullivan, Finbarr ^a   Link, Jeanne M ^a   Lewellen, Thomas K ^a   Lewellen, Barbara ^a   Freeman, Scott D ^a   Mankoff, David A ^a   Eary, Janet F ^a   Krohn, Kenneth A ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CELL DEATH; CLINICAL ARTICLE; CORRELATION FUNCTION; DISEASE COURSE; DRUG TUMOR LEVEL; ENERGY; GLIOBLASTOMA; GLUCOSE METABOLISM; HUMAN; HUMAN TISSUE; INFLAMMATORY INFILTRATE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; TUMOR CELL;

ADULT; AGED; FEMALE; FLUORODEOXYGLUCOSE F18; GLIOMA; GLUCOSE; HUMANS; MALE; MIDDLE AGED; RADIOPHARMACEUTICALS; SURVIVAL ANALYSIS; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED; TREATMENT OUTCOME;

EID: 0036554829     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Alavi, J. B., Alavi, A., Chawluk, J., Kushner, M., Powe, J., Hickey, W., and Reivich, M. Positron emission tomography in patients with glioma: a predictor of prognosis. Cancer (Phila.), 62: 1074-1078, 1988.
2. Coleman, R. E., Hoffman, J. M., Hanson, M. W., Sostman, H. D., and Schold, S. C. J. Clinical application of PET for the evaluation of brain tumors. J. Nucl. Med., 32: 616-622, 1991.
3. 18F] fluorodeoxyglucose in brain tumors: a powerful diagnostic and prognostic tool. Investig. Radiol., 22: 360-371, 1987.
4. Doyle, W. K., Budinger, T. F., Valk, P. E., Levin, V. A., and Gutin, P. H. Differentiation of cerebral radiation necrosis from tumor recurrence by [18F]FDG and 82Rb positron emission tomography. J. Comput. Assisted Tomogr., 11: 563-570, 1987.
5. Kim, E. E., Chung, S. K., Haynie, T. P., Kim, C. G., Cho, B. J., Podoloff, D. A., Tilbury, R. S., Yang, D. J., Yung, W. K., and Moser, R. P. J. Differentiation of residual or recurrent tumors from post-treatment changes with F-18 FDG PET. Radiographics, 12: 269-279, 1992.
6. Glantz, M. J., Hoffman, J. M., Coleman, R. E., Friedman, A. H., Hanson, M. W., Burger, P. C., Herndon, J. E., Meisler, W. J., and Schold, S. C. Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomography. Ann. Neurol., 29: 347-355, 1991.
7. Ishikawa, M., Kikuchi, H., Miyatake, S., Oda, Y., Yonekura, Y., and Nishizawa, S. Glucose consumption in recurrent gliomas. Neurosurgery (Baltimore), 33: 28-33, 1993.
8. Janus, T. J., Kim, E. E., Tilbury, R., Bruner, J. M., and Yung, W. K. Use of [18F]fluorodeoxyglucose positron emission tomography in patients with primary malignant brain tumors. Ann. Neurol., 33: 540-548, 1993.
9. Patronas, N. J., Di Chiro, G., Kufta, C., Bairamian, D., Kornblith, P. L., Simon, R., and Larson, S. M. Prediction of survival in glioma patients by means of positron emission tomography. J. Neurosurg., 62: 816-822, 1985.
10. Ricci, P. E., Karis, J. P., Heiserman, J. E., Fram, E. K., Bice, A. N., and Drayer, B. P. Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography? AJNR. Am. J. Neuroradiol., 19: 407-413, 1998.
11. Tyler, J. L., Diksic, M., Villemure, J. G., Evans, A. C., Meyer, E., Yamamoto, Y. L., and Feindel, W. Metabolic and hemodynamic evaluation of gliomas using positron emission tomography. J. Nucl. Med., 28: 1123-1133, 1987.
12. Valk, P. E., Budinger, T. F., Levin, V. A., Silver, P., Gutin, P. H., and Doyle, W. K. PET of malignant cerebral tumors after interstitial brachytherapy. J. Neurosurg., 69: 830-838, 1988.
13. American Academy of Neurology Therapeutics, and Technology Assessment Subcommittee Assessment. Positron emission tomography. Neurology, 41: 163-167, 1991.
14. Blasberg, R. G. Prediction of brain tumor therapy response by PET. J. Neuro-Oncol., 22: 281-286, 1994.
15. Hoekstra, C. J., Paglianiti, I., Hoekstra, O. S., Smit, E. F., Postmus, P. E., Teule, G. J., and Lammertsma, A. A. Monitoring response to therapy in cancer using [18F]-2-fluoro-2-deoxy-D-glucose and positron emission tomography: an overview of different analytical methods. Eur. J. Nucl. Med., 27: 731-743, 2000.
16. Holzer, T., Herholz, K., Jeske, J., and Heiss, W. D. FDG-PET as a prognostic indicator in radiochemotherapy of glioblastoma. J. Comput. Assisted Tomogr., 17: 681-687, 1993.
17. Mineura, K., Yasuda, T., Kowada, M., Ogawa, T., Shishido, F., and Uemura, K. Positron emission tomographic evaluation of radiochemotherapeutic effect on regional cerebral hemocirculation and metabolism in patients with gliomas. J. Neuro-Oncol., 5: 277-285, 1987.
18. Ogawa, T., Uemura, K., Shishido, F., Yamaguchi, T., Murakami, M., Inugami, A., Kanno, I., Sasaki, H., Kato, T., Hirata, K., Kowada, M., Mineura, K., and Yasuda, T. Changes of cerebral blood flow, and oxygen and glucose metabolism following radiochemotherapy of gliomas: a PET study. J. Comput. Assisted Tomogr., 12: 290-297, 1988.
19. Schifter, T., Hoffman, J. M., Hanson, M. W., Boyko, O. B., Beam, C., Paine, S., Schold, S. C., Burger, P. C., and Coleman, R. E. Serial FDG-PET studies in the prediction of survival in patients with primary brain tumors. J. Comput. Assisted Tomogr., 17: 509-516, 1993.
20. Graham, M. M., Muzi, M., Spence, A. M., O'Sullivan, F., Lewellen, T. K., Link, J. M., and Krohn, K. A. Regional FDG lumped constant in the normal human brain. In: A. Gjedde, S. B. Hansen, G. Knudsen, and O. B. Paulson (eds.), Physiological Imaging of the Brain with PET, pp. 115-120. San Diego: Academic Press, Inc., 2001.
21. Spence, A. M., Muzi, M., Graham, M. M., O'Sullivan, F., Krohn, K. A., Link, J. M., Lewellen, T. K., Lewellen, B., Freeman, S. D., Berger, M. S., and Ojemann, G. A. Glucose metabolism in human malignant gliomas measured quantitatively with PET, 1-[C-11]glucose and FDG: analysis of the FDG lumped constant. J. Nucl. Med., 39: 440-448, 1998.
22. Haberkorn, U., Strauss, L. G., Dimitrakopoulou, A., Engenhart, R., Oberdorfer, F., Ostertag, H., Romahn, J., and van Kaick, G. PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy. J. Nucl. Med., 32: 1485-1490, 1991.
23. Ichiya, Y., Kuwabara, Y., Otsuka, M., Tahara, T., Yoshikai, T., Fukumura, T., Jingu, K., and Masuda, K. Assessment of response to cancer therapy using fluorine-18-fluorodeoxyglucose and positron emission tomography. J. Nucl. Med., 32: 1655-1660, 1991.
24. Minn, H., Paul, R., and Ahonen, A. Evaluation of treatment response to radiotherapy in head and neck cancer with fluorine-18 fluorodeoxyglucose. J. Nucl. Med., 29: 1521-1525, 1988.
25. Curran, W. J. J., Scott, C. B., Horton, J., Nelson, J. S., Weinstein, A. S., Fischbach, A. J., Chang, C. H., Rotman, M., Asbell, S. O., Krisch, R. E., and Nelson, D. F. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J. Natl. Cancer. Inst., 85: 704-710, 1993.
26. Hamacher, K., Coenen, H. H., and Stocklin, G. Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J. Nucl. Med., 27: 235-238, 1986.
27. Shiue, C-Y., and Wolf, A. P. The synthesis of 1-[C-11]-D-glucose for measurement of brain glucose metabolism. J. Nucl. Med., 22: P58, 1981.
28. Shiue, C-Y., and Wolf, A. P. 1-11-C-D-glucose and related compounds. United States Patent # 4439414A. Washington, DC: United States Government Printing Office, 1984.
29. 11C]D-glucose. Appl. Radiat. Isot., 44: 971-980, 1993.
30. Lewellen, T. K., Bice, A. N., Harrison, R. L., Pencke, M. D., and Link, J. M. Performance measurements of the SP-3000/UW time-offlight emission tomograph. IEEE Trans. Nucl. Sci., 35: 665-667, 1988.
31. Lewellen, T. K., Bice, A. N., Miyaoka, R. S., and Harrison, R. L. Performance improvements for the SP-3000 time-of-flight positron emission tomograph. J. Nucl. Med., 31: 863, 1990.
32. Lewellen, T. K., Harrison, R. L., and Bice, A. N. An experimental evaluation of the effect of time-of-flight information in image reconstructions for the Scanditronix/PETT electronics SP-3000 positron emission tomograph-preliminary results. IEEE Trans. Nucl. Sci., 36: 1095- 1099, 1989.
33. DeGrado, T. R., Turkington, T. G., Williams, J. J., Stearns, C. W., Hoffman, J. M., and Coleman, R. E. Performance characteristics of a whole-body PET scanner. J. Nucl. Med., 35: 1398-1406, 1994.
34. Lewellen, T. K., Kohlmyer, S. G., Miyaoka, R. S., Kaplan, M. S., Stearns, C. W., and Schubert, S. F. Investigation of the performance of the General Electric ADVANCE positron emission tomograph in 3D mode. IEEE Trans. Nucl. Sci., 43: 2199-2206, 1996.
35. Lewellen, T. K., Kohlmyer, S. G., Miyaoka, R. S., Schubert, S., and Stearns, C. W. Investigation of the count rate performance of General Electric Advance positron emission tomograph. IEEE Trans. Nuclear. Sci., 42: 1051-1057, 1995.
36. Graham, M. M., and Lewellen, B. L. High-speed automated discrete blood sampling for positron emission tomography. J. Nucl. Med., 34: 1357-1360, 1993.
37. Blomqvist, G., Stone-Elander, S., Halldin, C., Roland, P. E., Widen, L., Lindqvist, M., Swahn, C-G., Langstrom, B., and Wiesel, F. A. Positron emission tomographic measurements of cerebral glucose utilization using [1-11-C]D-glucose. J. Cereb. Blood Flow Metab., 10: 467-483, 1990.
38. Phelps, M. E., Huang, S. C., Hoffman, E. J., Selin, C., Sokoloff, L., and Kuhl, D. E. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-D-glucose: validation of method. Ann. Neurol., 6: 371-388, 1979.
39. 14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J. Neurochem., 28: 897-916, 1977.
40. Dennis, J. E., Gay, D. M., and Welsch, R. E. An adaptive non-linear least squares algorithm. ACM Trans. on Math. Software, 7: 348-383, 1981.
41. Kalbfleisch, J. D., and Prentice, R. L. The Statistical Analysis of Failure Time Data, pp. 1-336. New York: Wiley, 1980.
42. Delbeke, D., Meyerowitz, C., Lapidus, R. L., Maciunas, R. J., Jennings, M. T., Moots, P. L., and Kessler, R. M. Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET. Radiology, 195: 47-52, 1995.
43. Barker, F. G., Chang, S. M., Valk, P. E., Pounds, T. R., and Prados, M. D. 18-Fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant glioma. Cancer (Phila.), 79: 115-126, 1997.
44. Langen, K. J., Roosen, N., Kuwert, T., Herzog, H., Kiwit, J. C., Rota Kops, E., Muzik, O., Bock, W. J., and Feinendegen, L. E. Early effects of intra-arterial chemotherapy in patients with brain tumors studied with PET: preliminary results. Nucl. Med. Commun., 10: 779-790, 1989.
45. Rozental, J. M., Levine, R. L., Nickles, R. J., and Dobkin, J. A. Glucose uptake by gliomas after treatment. Arch. Neurol., 46: 1302-1307, 1989.
46. Rozental, J. M., Levine, R. L., and Nickles, R. J. Changes in glucose uptake by malignant gliomas: preliminary study of prognostic significance. J. Neuro-Oncol., 10: 75-83, 1991.
47. De Witte, O., Hildebrand, J., Luxen, A., and Goldman, S. Acute effect of carmustine on glucose metabolism in brain and glioblastoma. Cancer (Phila.), 74: 2836-2842, 1994.
48. Maruyama, I., Sadato, N., Waki, A., Tsuchida, T., Yoshida, M., Fujibayashi, Y., Ishii, Y., Kubota, T., and Yonekura, Y. Hyperacute changes in glucose metabolism of brain tumors after stereotactic radiosurgery: a PET study. J. Nucl. Med., 40: 1085-1090, 1999.
49. Haberkorn, U., Bellemann, M. E., Altmann, A., Gerlach, L., Morr, I., Oberdorfer, F., Brix, G., Doll, J., Blatter, J., and van Kaick, G. PET 2-fluoro-2-deoxyglucose uptake in rat prostate adenocarcinoma during chemotherapy with gemcitabine. J. Nucl. Med., 38: 1215-1221, 1997.
50. Haberkorn, U., Morr, I., Oberdorfer, F., Bellemann, M. E., Blatter, J., Altmann, A., Kahn, B., and van Kaick, G. Fluorodeoxyglucose uptake in vitro: aspects of method and effects of treatment with gemcitabine. J. Nucl. Med., 35: 1842-1850, 1994.
51. Haberkorn, U., Oberdorfer, F., Klenner, T., Strauss, L. G., Stohr, M., Wallich, R., Altmann, A., and Kaick, G. V. Metabolic and transcriptional changes in osteosarcoma cells treated with chemotherapeutic drugs. Nucl. Med. Biol., 21: 835-845, 1994.
52. Haberkorn, U., Reinhardt, M., Strauss, L. G., Oberdorfer, F., Berger, M. R., Altmann, A., Wallich, R., Dimitrakopoulou, A., and van Kaick, G. Metabolic design of combination therapy: use of enhanced fluorodeoxyglucose uptake caused by chemotherapy. J. Nucl. Med., 33: 1981-1987, 1992.
53. Smith, T. A., Maisey, N. R., Titley, J. C., Jackson, L. E., Leach, M. O., and Ronen, S. M. Treatment of SW620 cells with Tomudex and oxaliplatin induces changes in 2-deoxy-D-glucose incorporation associated with modifications in glucose transport. J. Nucl. Med., 41: 1753-1759, 2000.
54. Higashi, K., Clavo, A. C., and Wahl, R. L. In vitro assessment of 2-fluoro-2-deoxy-D-glucose, L-methionine and thymidine as agents to monitor the early response of a human adenocarcinoma cell line to radiotherapy. J. Nucl. Med., 34: 773-779, 1993.
55. Fujibayashi, Y., Waki, A., Sakahara, H., Konishi, J., Yonekura, Y., Ishii, Y., and Yokoyama, A. Transient increase in glycolytic metabolism in cultured tumor cells immediately after exposure to ionizing radiation: from gene expression to deoxyglucose uptake. Radiat. Res., 147: 729-734, 1997.
56. Kubota, R., Yamada, S., Kubota, K., Ishiwata, K., Tamahashi, N., and Ido, T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J. Nucl. Med., 33: 1972-1980, 1992.
57. Reinhardt, M. J., Kubota, K., Yamada, S., Iwata, R., and Yaegashi, H. Assessment of cancer recurrence in residual tumors after fractionated radiotherapy: a comparison of fluorodeoxyglucose. L-methionine and thymidine. J. Nucl. Med., 38: 280-287, 1997.
58. Cokgor, I., Akabani, G., Kuan, C. T., Friedman, H. S., Friedman, A. H., Coleman, R. E., McLendon, R. E., Bigner, S. H., Zhao, X. G., Garcia-Turner, A. M., Pegram, C. N., Wikstrand, C. J., Shafman, T. D., Herndon, J. E., Provenzale, J. M., Zalutsky, M. R., and Bigner, D. D. Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas. J. Clin. Oncol., 18: 3862-3872, 2000.
59. Furuta, M., Hasegawa, M., Hayakawa, K., Yamakawa, M., Ishikawa, H., Nonaka, T., Mitsuhashi, N., and Niibe, H. Rapid rise in FDG uptake in an irradiated human tumour xenograft. Eur. J. Nucl. Med., 24: 435-438, 1997.
60. Hasegawa, M., Mitsuhashi, N., Yamakawa, M., Furuta, M., Maebayashi, K., Imai, R., Hayakawa, K., and Niibe, H. p53 protein expression and radiation-induced apoptosis in human tumors transplanted to nude mice. Radiat. Med., 15: 171-176, 1997.